There were no significant associations between PFS and factors such as gender, age, tumor functional status, Ki-67 index, tumor grade, presence of MEN1 syndrome, use of other anti-tumor treatments or previous surgical intervention before surufatinib treatment (P = 0.858, P = 0.612, P = 0.240, P = 0.646, P = 0.598, P = 0.105, P = 0.133, P = 0.481), as shown in Table 2 and Figure 1. The gene discussed is MKI67; the disease is multiple endocrine neoplasia type 1.